Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 1;6(6):1598–1607. doi: 10.4161/mabs.36089

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Author(s). Published with license by Taylor & Francis Group, LLC

© Feifan Yu, Lindvi Gudmundsdotter, Anastassja Akal, Elin Gunneriusson, Fredrik Frejd, and Per-Åke Nygren

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 7. — Analysis of the therapeutic effect of the AffiMab Z_{IL-6_13}-HC_Ada hybrid in an acute SAA model. The AffiMab Z_{IL-6_13}-HC_Ada, corresponding to a hybrid construct between the anti-IL-6 affibody Z_{IL-6_13} and the anti-TNF antibody adalimumab was analyzed in a mouse model for acute Serum amyloid A (SAA). For comparison, the effect of unmodified adalimumab was also tested in parallel. AffiMab or adalimumab doses of different concentrations were given nine hours before the animals (groups of six) were injected i.p. with a mixture of 2.5 μg/kg body weight each of TNF and IL-6 to trigger SAA production, which was analyzed 16 h post TNF/IL-6 injection. See text for details.